DUBLIN–(BUSINESS WIRE)–The “A Practical Approach to Veterinary Vaccine Development and Registration in the EU (European Union) Training Course (Mar 10th – Mar 11thDUBLIN–(BUSINESS WIRE)–The “A Practical Approach to Veterinary Vaccine Development and Registration in the EU (European Union) Training Course (Mar 10th – Mar 11th

A Practical Approach to Veterinary Vaccine Development and Registration in the EU (European Union) Training Course (Mar 10th – Mar 11th, 2026) – ResearchAndMarkets.com

2025/12/30 01:00
4분 읽기
이 콘텐츠에 대한 의견이나 우려 사항이 있으시면 crypto.news@mexc.com으로 연락주시기 바랍니다

DUBLIN–(BUSINESS WIRE)–The “A Practical Approach to Veterinary Vaccine Development and Registration in the EU (European Union) Training Course (Mar 10th – Mar 11th, 2026)” training has been added to ResearchAndMarkets.com’s offering.

Demand for biologics in veterinary medicine is increasing. However, developing vaccines and successfully obtaining market authorisation brings its own complex and challenging issues.

This course has been designed to give practical advice and guidance on how to successfully develop a veterinary vaccine and achieve market approval in the EU, ensuring that participants gain a comprehensive insight into the necessary requirements.

The programme will take a step-by-step approach to the process and will include a workshop to help delegates gain a better understanding of the requirements in practice. There will be ample time for discussion throughout the two days with our expert faculty and fellow professionals.

Benefits of attending

  • Recognise the key legislation and guidance and how to use this to plan an effective veterinary vaccine development
  • Understand what data you need to generate for your application and how to present this in your dossier
  • Gain an insight into the different routes to market and how to submit your dossier for market approval
  • Learn how and when to seek regulatory advice during development
  • Consider the implications of the ongoing review of the Veterinary Medicines Regulations

Who Should Attend:

This event will be beneficial to all those working with veterinary vaccines from development to market approval.

The programme will be of particular interest to:

  • New entrants to registration departments
  • Veterinary medicinal product manufacturers
  • Registration managers
  • Research and development departments
  • Academics with an interest in commercialising opportunities
  • Personnel from micro/small and medium-sized enterprises (SMEs)

Certifications:

  • CPD: 12 hours for your records
  • Certificate of completion

Key Topics Covered:

Day 1

A practical guide to the EU regulatory framework for veterinary vaccines

  • Regulatory bodies
  • Key legislation and guidance
  • Update on the legislation review

Meeting the requirements of the marketing authorisation dossier – part 2: quality

  • Legislation and guidance
  • Layout and content of the Part 2 dossier

Meeting the requirements of the marketing authorisation dossier – part 3: safety

  • Legislation and guidance
  • Data requirements for the demonstration of safety
  • Layout of the Part 3 dossier

Meeting the requirements of the marketing authorisation dossier – part 4: efficacy

  • Legislation and guidance
  • Data requirements for the demonstration of efficacy
  • Layout of the Part 4 dossier

Day 2

Using the summary of product characteristics (SmPC) as a tool for development

Planning a vaccine development – introduction and workshop

Workshop – groups report back and Q&A

Preparing the dossier submission

  • Marketing authorisation dossier – Part 1: Administrative documentation, DACS and benefit risk assessments and product information
  • Tips on dossier writing and e-submissions

European licensing procedures and regulatory strategy

  • Centralised procedure
  • Decentralised procedure
  • Mutual recognition procedure
  • Regulatory strategy

Seeking regulatory advice and development of novel vaccines

  • Meetings with regulators
  • Scientific advice
  • Innovation Task Force (ITF)

Procedures aimed at promoting innovation and vaccine availability

  • Minor use/minor species (MUMS) classification
  • Small/medium enterprise (SME) designation
  • EMA network strategy 2020

Speakers:

Mel Munro

Management Forum

Mel has worked in regulatory affairs in the Animal Health Industry since 2002. She has been involved in all aspects of veterinary vaccine development and spends most of her time assisting clients with Start-to-Finish projects, taking ideas for veterinary medicines from proof of concept right through to Marketing Authorisations (MA).

On a daily basis Mel is responsible for preparing reports, documents and Dossiers for MA submissions, and for running National, Decentralised and Centralised Procedures. She also provides gap analysis of existing products and strategic advice on new product developments.

Over her career she has been involved in various vaccine development projects ranging from inactivated and live viral and bacterial vaccines, to novel vaccines that include products of rDNA technology and GMO’s.

For more information about this training visit https://www.researchandmarkets.com/r/y6vavs

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, crypto.news@mexc.com으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.

USD1 Genesis: 0 Fees + 12% APR

USD1 Genesis: 0 Fees + 12% APRUSD1 Genesis: 0 Fees + 12% APR

New users: stake for up to 600% APR. Limited time!